<?xml version='1.0' encoding='utf-8'?>
<document id="16611859"><sentence text="Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole."><entity charOffset="54-63" id="DDI-PubMed.16611859.s1.e0" text="midazolam" /><entity charOffset="77-89" id="DDI-PubMed.16611859.s1.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.16611859.s1.e0" e2="DDI-PubMed.16611859.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s1.e0" e2="DDI-PubMed.16611859.s1.e1" /></sentence><sentence text="Conventional methods to forecast CYP3A-mediated drug-drug interactions have not employed stochastic approaches that integrate pharmacokinetic (PK) variability and relevant covariates to predict inhibition in terms of probability and uncertainty" /><sentence text=" Empirical approaches to predict the extent of inhibition may not account for nonlinear or non-steady-state conditions, such as first-pass effects or accumulation of inhibitor concentration with multiple dosing" /><sentence text=" A physiologically based PK model was developed to predict the inhibition of CYP3A by ketoconazole (KTZ), using midazolam (MDZ) as the substrate"><entity charOffset="86-98" id="DDI-PubMed.16611859.s4.e0" text="ketoconazole" /><entity charOffset="100-103" id="DDI-PubMed.16611859.s4.e1" text="KTZ" /><entity charOffset="112-121" id="DDI-PubMed.16611859.s4.e2" text="midazolam" /><entity charOffset="123-126" id="DDI-PubMed.16611859.s4.e3" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e0" e2="DDI-PubMed.16611859.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e0" e2="DDI-PubMed.16611859.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e0" e2="DDI-PubMed.16611859.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e0" e2="DDI-PubMed.16611859.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e1" e2="DDI-PubMed.16611859.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e1" e2="DDI-PubMed.16611859.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e1" e2="DDI-PubMed.16611859.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e2" e2="DDI-PubMed.16611859.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s4.e2" e2="DDI-PubMed.16611859.s4.e3" /></sentence><sentence text=" The model integrated PK models of MDZ and KTZ, in vitro inhibition kinetics of KTZ, and the variability and uncertainty associated with these parameters"><entity charOffset="43-45" id="DDI-PubMed.16611859.s5.e0" text="KTZ" /><entity charOffset="80-82" id="DDI-PubMed.16611859.s5.e1" text="KTZ" /><entity charOffset="35-37" id="DDI-PubMed.16611859.s5.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s5.e2" e2="DDI-PubMed.16611859.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s5.e2" e2="DDI-PubMed.16611859.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s5.e2" e2="DDI-PubMed.16611859.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16611859.s5.e0" e2="DDI-PubMed.16611859.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s5.e0" e2="DDI-PubMed.16611859.s5.e1" /></sentence><sentence text=" This model predicted the time- and dose-dependent inhibitory effect of KTZ on MDZ oral clearance"><entity charOffset="72-74" id="DDI-PubMed.16611859.s6.e0" text="KTZ" /><entity charOffset="79-81" id="DDI-PubMed.16611859.s6.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s6.e0" e2="DDI-PubMed.16611859.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s6.e0" e2="DDI-PubMed.16611859.s6.e1" /></sentence><sentence text=" The predictive performance of the model was validated using the results of five published KTZ-MDZ studies"><entity charOffset="91-93" id="DDI-PubMed.16611859.s7.e0" text="KTZ" /><entity charOffset="95-97" id="DDI-PubMed.16611859.s7.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s7.e0" e2="DDI-PubMed.16611859.s7.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s7.e0" e2="DDI-PubMed.16611859.s7.e1" /></sentence><sentence text=" The model improves the accuracy of predicting the inhibitory effect of increasing KTZ dosing on MDZ PK by incorporating a saturable KTZ efflux from the site of enzyme inhibition in the liver"><entity charOffset="83-85" id="DDI-PubMed.16611859.s8.e0" text="KTZ" /><entity charOffset="133-135" id="DDI-PubMed.16611859.s8.e1" text="KTZ" /><entity charOffset="97-99" id="DDI-PubMed.16611859.s8.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s8.e0" e2="DDI-PubMed.16611859.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s8.e0" e2="DDI-PubMed.16611859.s8.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s8.e0" e2="DDI-PubMed.16611859.s8.e1" /><pair ddi="false" e1="DDI-PubMed.16611859.s8.e2" e2="DDI-PubMed.16611859.s8.e2" /><pair ddi="false" e1="DDI-PubMed.16611859.s8.e2" e2="DDI-PubMed.16611859.s8.e1" /></sentence><sentence text=" The results of simulations using the model supported the KTZ dose of 400 mg once daily as the optimal regimen to achieve maximum inhibition by KTZ"><entity charOffset="58-60" id="DDI-PubMed.16611859.s9.e0" text="KTZ" /><entity charOffset="144-146" id="DDI-PubMed.16611859.s9.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.16611859.s9.e0" e2="DDI-PubMed.16611859.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16611859.s9.e0" e2="DDI-PubMed.16611859.s9.e1" /></sentence><sentence text=" Sensitivity analyses revealed that the most influential variable on the prediction of inhibition was the fractional clearance of MDZ mediated by CYP3A"><entity charOffset="130-132" id="DDI-PubMed.16611859.s10.e0" text="MDZ" /></sentence><sentence text=" The model may be used prospectively to improve the quantitative prediction of CYP3A inhibition and aid the optimization of study designs for CYP3A-mediated drug-drug interaction studies in drug development" /><sentence text="" /></document>